Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by Oak Thistle LLC

Oak Thistle LLC decreased its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 53.1% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,557 shares of the medical device company’s stock after selling 9,694 shares during the period. Oak Thistle LLC’s holdings in Tandem Diabetes Care were worth $303,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. MCF Advisors LLC boosted its holdings in Tandem Diabetes Care by 79.3% in the first quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock valued at $36,000 after acquiring an additional 445 shares during the last quarter. Van ECK Associates Corp boosted its holdings in Tandem Diabetes Care by 8.6% in the fourth quarter. Van ECK Associates Corp now owns 5,900 shares of the medical device company’s stock valued at $175,000 after acquiring an additional 467 shares during the last quarter. Diversified Trust Co boosted its holdings in Tandem Diabetes Care by 5.6% in the fourth quarter. Diversified Trust Co now owns 10,573 shares of the medical device company’s stock valued at $313,000 after acquiring an additional 564 shares during the last quarter. RiverPark Advisors LLC acquired a new position in Tandem Diabetes Care in the fourth quarter valued at $27,000. Finally, PNC Financial Services Group Inc. boosted its holdings in Tandem Diabetes Care by 51.7% in the third quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the medical device company’s stock valued at $67,000 after acquiring an additional 1,099 shares during the last quarter.

Tandem Diabetes Care Stock Performance

TNDM stock traded down $0.84 on Monday, reaching $39.45. The company’s stock had a trading volume of 1,500,848 shares, compared to its average volume of 1,736,491. Tandem Diabetes Care, Inc. has a 52 week low of $13.82 and a 52 week high of $53.69. The company has a market capitalization of $2.55 billion, a P/E ratio of -18.18 and a beta of 1.28. The firm has a fifty day moving average of $44.68 and a two-hundred day moving average of $34.05. The company has a debt-to-equity ratio of 1.43, a current ratio of 3.81 and a quick ratio of 3.01.

Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings results on Thursday, May 2nd. The medical device company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.17. The firm had revenue of $191.67 million during the quarter, compared to the consensus estimate of $173.06 million. Tandem Diabetes Care had a negative return on equity of 34.38% and a negative net margin of 18.37%. As a group, analysts predict that Tandem Diabetes Care, Inc. will post -1.71 EPS for the current fiscal year.

Insider Activity

In other news, Director Dick Allen sold 5,000 shares of the stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $51.68, for a total transaction of $258,400.00. Following the completion of the sale, the director now owns 24,396 shares in the company, valued at approximately $1,260,785.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 2.20% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on TNDM shares. StockNews.com upgraded Tandem Diabetes Care from a “sell” rating to a “hold” rating in a report on Friday, April 19th. Lake Street Capital boosted their price objective on Tandem Diabetes Care from $60.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, May 22nd. Leerink Partnrs upgraded Tandem Diabetes Care from a “market perform” rating to an “outperform” rating in a research note on Thursday, April 25th. Citigroup upgraded Tandem Diabetes Care from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $40.00 to $57.00 in a research note on Wednesday, May 22nd. Finally, Barclays boosted their price objective on Tandem Diabetes Care from $39.00 to $55.00 and gave the stock an “overweight” rating in a research note on Monday, May 6th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $51.25.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.